jump to navigation

India 2nd best innovation facilitator places in the World May 17, 2007

Posted by mais in IPM Strategies.
add a comment

India emerged as the country with 2nd best conditions for innovation, after the US. UK ranked third and Japan at the fourth.

Japan has emerged as the world’s most innovative nation in terms of business practises, followed by Switzerland, US and Sweden. India has been ranked at 58th position, ahead of China’s 59th position in a ranking of 82 economies, based on their level of innovation during 2002-06. India fared marginally better on a study of innovation enablers (or the ability of a country to facilitate innovation), coming in at No. 50.

The Economic Intelligence Unit, The Economist, survyed 485 senior executives worldwide and analysed data collected between 2002 and 2006. 

A forecast by the agency for 2007-2011 expects China to improve its rank by five positions, while India is expected to move up by two. Hence, India will give away its lead over China as an innovative country in the next five years.

The top four will maintain their positions, according to the forecast, while China will move up five places to 54th and Mexico will climb six places to 39th.

Indian firms and brazilian AIDS patients to be benefit from compulsory licensing May 9, 2007

Posted by mais in Drugs, India, Patent, TRIPS, WTO.
add a comment

The Brazilian government’s decision to override the patent rights of Merck’s HIV/AIDS drug Stocrin (efavirenz) and buy reverse engineered generic versions of the drug at low cost has come as a boon for Indian pharmaceutical companies manufacturing generic versions of efavirenz such as Cipla, Ranbaxy, Aurobindo Pharma and Strides Arcolab.

On Friday, Brazilian President Luiz Inacio Lula da Silva announced invoking the compulsory licensing provision for pharmaceuticals under the World Trade Organisation’s (WTO) agreement on intellectual property – the TRIPS (Trade-Related Aspects of Intellectual Property Rights) – to buy copycat versions of efavirenz from laboratories certified by the World Health Organisation.

With over 200,000 registered cases, Brazil has the most AIDS patients in Latin America. Of them, only 75,000 patients are currently treated with efavirenz.

Welcoming the Brazilian government’s move, Amar Lulla, joint managing director of Cipla, said it was heartening to note that Brazil has invoked the compulsory licensing provision to treat its HIV/AIDS patients with affordable generic drugs.

“The compulsory licensing provision of the TRIPS help countries to protect the rights of its citizens. We welcome the Brazilian move,” he said.

Lulla confirmed that the Brazilian government was negotiating with Cipla for the supply of these medicines.

Follow

Get every new post delivered to your Inbox.